Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Molecular basis and clinical perspectives of deep brain stimulation for major depressive disorder.

Authors:
Saulo Araújo Teixeira Jorge Lucas de Sousa Moreira Narah Régia Tavares Sousa Andrezza Maria de Carvalho Pereira Paloma Nóbrega Rodrigues Adriano Siqueira Dos Santos Ana Maria Lima Carneiro de Andrade Modesto Leite Rolim Neto Jaime Emanuel Brito Araújo Sávio Samuel Feitosa Machado Nélio Barreto Vieira Danielly Gonçalves Sombra Lima Francisco Helder Pereira Filho

J Cereb Blood Flow Metab 2022 04 20;42(4):683-685. Epub 2022 Jan 20.

School of Medicine - Universidad Central del Paraguay - Sede 2 - Asunción, Paraguay.

It is possible to consider the stimulation of the cingulate gyrus in its portion below the corpus callosum (SCC, or subcallosal cingulate cortex) as an effective, promising, and safe alternative intervention for treatment-resistant depression. In studies with deep brain stimulation - DBS, when follow-on with functional magnetic resonance imaging and/or PET-CT (Positron emission tomography-computed tomography) is performed, it is observed an increase in the blood supply and glucose metabolism in this region, which is the anterior part of the limbic system. This same location has good experimental results also for the treatment of anorexia nervosa. The hypotheses suggest a greater activation of the reward system, a greater sense of well-being, and a consequent reduction in depressive symptoms, the objective of the treatment. Over the last 20 years, multicenter studies have shown symptomatic improvement in 50-60% of patients, and about a third even reach criteria for remission of the depressive disorder.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0271678X221074279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051149PMC
April 2022

Publication Analysis

Top Keywords

depressive disorder
8
deep brain
8
brain stimulation
8
remission depressive
4
imaging and/or
4
tomography-computed tomography
4
well-being consequent
4
emission tomography-computed
4
positron emission
4
consequent reduction
4
pet-ct positron
4
reduction depressive
4
and/or pet-ct
4
resonance imaging
4
depressive symptoms
4
tomography performed
4
magnetic resonance
4
symptoms objective
4
functional magnetic
4
objective treatment
4

Keyword Occurance

Similar Publications

Functional MRI in major depressive disorder: A review of findings, limitations, and future prospects.

Authors:
Jesper Pilmeyer Willem Huijbers Rolf Lamerichs Jacobus F A Jansen Marcel Breeuwer Svitlana Zinger

J Neuroimaging 2022 May 21. Epub 2022 May 21.

Department of Electrical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

Objective diagnosis and prognosis in major depressive disorder (MDD) remains a challenge due to the absence of biomarkers based on physiological parameters or medical tests. Numerous studies have been conducted to identify functional magnetic resonance imaging-based biomarkers of depression that either objectively differentiate patients with depression from healthy subjects, predict personalized treatment outcome, or characterize biological subtypes of depression. While there are some findings of consistent functional biomarkers, there is still lack of robust data acquisition and analysis methodology. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Stress-induced despair behavior develops independently of the Ahr-RORγt axis in CD4 + cells.

Authors:
Courtney R Rivet-Noor Andrea R Merchak Sihan Li Rebecca M Beiter Sangwoo Lee Jalon Aaron Thomas Anthony Fernández-Castañeda Jung-Bum Shin Alban Gaultier

Sci Rep 2022 May 21;12(1):8594. Epub 2022 May 21.

Center for Brain Immunology and Glia, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.

Current treatments for major depressive disorder are limited to neuropharmacological approaches and are ineffective for large numbers of patients. Recently, alternative means have been explored to understand the etiology of depression. Specifically, changes in the microbiome and immune system have been observed in both clinical settings and in mouse models. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Corrigendum to "Abnormal brain gray matter volume in patients with major depressive disorder: Associated with childhood trauma?" [J. Affect. Disord. Volume 308, 1 July 2022, 562-568].

Authors:
Yahui Liu Jiajia Zhang Meng Zhang Xianrui Li Kun Li Bi Wang Yongfeng Yang Ruize Song Yajing Si Tianjun Ni Xueke Wang Yibo Geng Qiaohua Chang Haisan Zhang Zhijun Zhang Hongxing Zhang

J Affect Disord 2022 May 18. Epub 2022 May 18.

Department of Psychology, Xinxiang Medical University, Henan 453003, China; Xinxiang Key Laboratory of Psychopathology and Cognitive Neuroscience, Xinxiang 453003, China; Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453002, China. Electronic address:

View Article and Full-Text PDF
May 2022
Similar Publications

Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.

Authors:
David S Baldwin Oscar Necking Simon Nitschky Schmidt Hongye Ren Elin H Reines

J Affect Disord 2022 May 18. Epub 2022 May 18.

H. Lundbeck A/S; Valby, Denmark.

Background: The multimodal antidepressant vortioxetine is effective in reducing somatic symptoms in patients with major depressive disorder (MDD), but little is known about its effects in reducing depressive symptoms in patients with common comorbid physical illnesses.

Methods: This was a pooled analysis of 13 randomized, placebo-controlled trials which evaluated the efficacy (using the Montgomery-Åsberg Depression Rating Scale [MADRS]) and safety of vortioxetine (5-20 mg/day) in adult patients with MDD. We evaluated stable somatic comorbid conditions that were verified by a diagnosis and had sufficient database representation. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap